Results 171 to 180 of about 7,681 (214)
Some of the next articles are maybe not open access.
The Lancet Respiratory Medicine, 2015
To the Editor: Kerstjens et al. (Sept. 27 issue)1 report a 21% reduction in the risk of asthma exacerbation associated with tiotropium, along with a significant but small improvement in the forced expiratory volume in 1 second (FEV1), which was less than the minimal clinically important difference of 230 ml.2 We think it is hard to explain the effect ...
openaire +3 more sources
To the Editor: Kerstjens et al. (Sept. 27 issue)1 report a 21% reduction in the risk of asthma exacerbation associated with tiotropium, along with a significant but small improvement in the forced expiratory volume in 1 second (FEV1), which was less than the minimal clinically important difference of 230 ml.2 We think it is hard to explain the effect ...
openaire +3 more sources
Expert Opinion on Investigational Drugs, 2001
Tiotropium bromide is a new long-lasting anticholinergic drug which, like ipratropium bromide, is a quaternary ammonium derivative. It binds with high affinity to muscarinic receptors but dissociates very slowly from M(1)- and M(3)-muscarinic receptors.
openaire +2 more sources
Tiotropium bromide is a new long-lasting anticholinergic drug which, like ipratropium bromide, is a quaternary ammonium derivative. It binds with high affinity to muscarinic receptors but dissociates very slowly from M(1)- and M(3)-muscarinic receptors.
openaire +2 more sources
The Pharmacological Properties of Tiotropium
Chest, 2000Tiotropium is a long-acting anticholinergic drug. Studies with cloned human muscarinic receptors show that tiotropium binds equally well to M(1), M(2), and M(3) receptors. However, it dissociates very slowly from M(1) and M(3) receptors compared with ipratropium, and more rapidly from M(2) receptors.
openaire +2 more sources
Tiotropium for Asthma — Promise and Caution
New England Journal of Medicine, 2012Anticholinergic agents have been available for the treatment of airways obstruction for many decades. For patients with chronic obstructive pulmonary disease (COPD), many practitioners believe that these drugs have become the bronchodilator of choice.
openaire +2 more sources
Tiotropium/Olodaterol: A Review in COPD
Drugs, 2015Tiotropium/olodaterol (Stiolto™ Respimat®, Spiolto™ Respimat®) is a fixed-dose combination of the long-acting antimuscarinic agent tiotropium bromide (hereafter referred to as tiotropium) and the long-acting β2-adrenoreceptor agonist olodaterol delivered via the Respimat® Soft Mist™ inhaler.
Sohita Dhillon, Dhillon Sohita
exaly +3 more sources
Tiotropium in the Treatment of Patients with Asthma
Southern Medical Journal, 2014Asthma is a chronic disease with a significant disease burden, and many patients fail to achieve disease control despite recommended medical therapy. Recent evidence suggests that there may be benefits to the use of the long-acting anticholinergic agent tiotropium in patients with asthma.We performed a systematic review of the literature to determine ...
Qura, Rashid, Robin, Klein
openaire +2 more sources
The Safety of Tiotropium — The FDA's Conclusions
New England Journal of Medicine, 2010Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide, and the rate of COPD-related death is increasing.1 No current drug therapy alters the progressive decline in lung function that characterizes this disease. In 2004, the Food and Drug Administration (FDA) approved the use of tiotropium delivered by the HandiHaler device,
Theresa M, Michele +2 more
openaire +2 more sources
Tiotropium for the treatment of asthma in adolescents
Expert Opinion on Pharmacotherapy, 2017Asthma is a prevalent disease affecting millions of individuals. Despite receiving guideline therapy with inhaled corticosteroids (ICS) with or without a long-acting β2-agonist (LABA), a proportion of patients remain symptomatic or have suboptimal lung function. There is therefore an unmet need for additional therapies to improve asthma control.
Eckard, Hamelmann +2 more
openaire +2 more sources